SyntekaBio

Syntekabio develops and provides AI-based drug discovery platforms built on three-dimensional protein structure and genomic big-data processing technology, including its small-molecule discovery platform DeepMatcher, the neoantigen prediction platform NEO-ARS, and the antibody/small-molecule platforms Sm-ARS and Ab-ARS.

Using these technologies, the company runs its core AI Driven Asset Program business model, which proactively discovers candidates, verifies them through global CROs, and pursues licensing deals.

It also operates its self-built AI supercomputing data center (ABS) to provide data center and systems integration services that serve as a cash-generating base. More recently it signed a colocation service supply agreement with cloud specialist Attoresearch, expanding infrastructure-based revenue.

On the pipeline side, the company has disclosed seven programs spanning small-molecule candidates for COPD, acute myeloid leukemia, Alzheimer's disease, and colorectal cancer, along with candidates for atopic dermatitis, depression, and alopecia, plus eight biobetter candidates targeting global blockbuster antibodies such as Keytruda and Dupixent.

It conducts joint development with overseas institutions such as QIMR Berghofer and Kanzen Biotechnology in Australia, and partners domestically with the Korea Research Institute of Chemical Technology and the Daegu-Gyeongbuk Medical Innovation Foundation.

The company is also pursuing a business-scope expansion into diagnostics, precision medicine, pharmaceuticals and medical devices, animal drugs and vaccines, and health functional foods to diversify revenue sources by leveraging its existing AI and genomics capabilities.

Competitively, it is often compared with drug-repurposing specialist Oncocross and LG Chem's integrated drug discovery AI platform, with its self-owned supercomputing infrastructure cited as a differentiating factor among listed peers.

Annual revenue was largely stagnant at KRW 244 million in 2022, KRW 123 million in 2023, and KRW 121 million in 2024, before surging to KRW 3.429 billion in 2025.

Operating losses, however, stayed above KRW 10 billion for four consecutive years: KRW 11.79 billion in 2022, KRW 12.28 billion in 2023, KRW 14.27 billion in 2024, and KRW 10.76 billion in 2025.

Net loss attributable to owners fluctuated from KRW 4.51 billion in 2022 to KRW 11.40 billion in 2023 and KRW 7.21 billion in 2024, before widening to KRW 17.38 billion in 2025, the largest annual loss in the period.

On a quarterly basis, fourth-quarter 2025 revenue climbed to KRW 1.759 billion, driving the annual revenue increase, though operating loss stood at KRW 2.490 billion and net loss at KRW 4.008 billion for the quarter.

Revenue then narrowed to KRW 422 million in the first quarter of 2026, with an operating loss of KRW 3.506 billion and net loss of KRW 3.492 billion, before revenue of KRW 449 million and a somewhat smaller operating loss of KRW 2.223 billion and net loss of KRW 2.204 billion in the second quarter of 2026.

Over the trailing four quarters (third quarter 2025 through second quarter 2026), the net loss attributable to owners totaled roughly KRW 12.008 billion, underscoring that large-scale losses continue.

Operating cash flow was consistently negative, with outflows of KRW 8-10.6 billion annually from 2022 through 2025, indicating the business remains dependent on external financing to continue operations.

The debt ratio held roughly steady at 77.0% in 2022 and 75.3% in 2024 before falling to 46.4% in 2025 following capital-raising activity.

The global AI drug discovery market is shifting toward competition on discovery-stage efficiency, with a March 16, 2026 report from Eugene Investment & Securities noting that the ability to quickly secure valid candidates with fewer experiments determines added value.

The report described the drug development value chain as running from discovery through preclinical, clinical, CDMO, and commercialization stages, with discovery-stage data capability emerging as the key competitive edge.

Domestically, drug-repurposing specialist Oncocross and LG Chem, which operates the integrated AI platform MedeeX across the full drug discovery cycle, are cited as comparison points.

Syntekabio positions itself as the only listed Korean company with its own supercomputing infrastructure, though its revenue scale remains small relative to peers.

On the policy front, Korea's Financial Services Commission and Korea Exchange have been running an intensive delisting management period from February 2026 through June 2027, raising exit pressure on distressed listed firms, which adds to listing-maintenance burdens across revenue-weak technology-listed biotech companies.

Indeed, at the time of half-year report filings in 2026, ten biotech and healthcare listed firms including Syntekabio received disclaimers of opinion, highlighting sector-wide accounting reliability concerns.

Under the technology special listing system, revenue requirements are waived for a set period after listing, but companies whose grace period has ended can be designated as administrative issues if they fail to meet quantitative criteria such as KRW 3 billion in revenue, putting growth pressure on numerous biotech firms in a position similar to Syntekabio.

The company plans to bring a charter amendment expanding its business scope into diagnostics, precision medicine, pharmaceuticals and medical devices, animal drugs and vaccines, and health functional foods to a vote at its extraordinary shareholders' meeting on September 15, alongside its existing AI drug discovery business, prioritizing the most commercially promising areas for phased monetization.

A company representative said the scope expansion is not a change in direction but an effort to broaden the use of accumulated technology and infrastructure to secure earlier revenue sources.

At the same time, the company is pursuing management normalization following the disclaimer of opinion on its half-year review, stating it aims to prepare the necessary materials and procedures to expedite a re-audit and secure an unqualified opinion.

If the re-audit results in a clean opinion, the company plans to pursue removal from investment caution stock designation.

On the business side, the KRW 6.48 billion colocation supply contract signed with Attoresearch in July 2026 is set to begin revenue recognition from November 1, 2026, which is expected to contribute to top-line growth in the second half.

However, with first-half revenue at only about KRW 872 million, second-half revenue would need to increase substantially to clear the KRW 3 billion annual threshold relevant to administrative-issue designation.

Eugene Investment & Securities forecast in March 2026 that annual 2026 revenue would reach KRW 7.7 billion with operating loss shrinking roughly 80% year over year, but given first-half results and the audit opinion issue, whether that forecast materializes will need to be reconfirmed against second-half results.

In addition, the maturity of a KRW 25 billion unsecured private convertible bond on November 30, 2026 remains a variable to watch for future liquidity, whether repaid or refinanced.